![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAGE2 |
Gene summary for PAGE2 |
![]() |
Gene information | Species | Human | Gene symbol | PAGE2 | Gene ID | 203569 |
Gene name | PAGE family member 2 | |
Gene Alias | CT16.4 | |
Cytomap | Xp11.21 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q7Z2X7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
203569 | PAGE2 | S014 | Human | Liver | HCC | 2.31e-81 | 2.71e+00 | 0.2254 |
203569 | PAGE2 | S015 | Human | Liver | HCC | 9.34e-34 | 2.38e+00 | 0.2375 |
203569 | PAGE2 | S016 | Human | Liver | HCC | 2.54e-92 | 2.91e+00 | 0.2243 |
203569 | PAGE2 | ATC09 | Human | Thyroid | ATC | 1.76e-29 | 9.53e-01 | 0.2871 |
203569 | PAGE2 | ATC1 | Human | Thyroid | ATC | 2.32e-29 | 1.14e+00 | 0.2878 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAGE2 | SNV | Missense_Mutation | c.199N>T | p.Asp67Tyr | p.D67Y | Q7Z2X7 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PAGE2 | SNV | Missense_Mutation | novel | c.95C>T | p.Pro32Leu | p.P32L | Q7Z2X7 | protein_coding | tolerated(0.11) | benign(0.028) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PAGE2 | SNV | Missense_Mutation | c.274N>A | p.Glu92Lys | p.E92K | Q7Z2X7 | protein_coding | tolerated(0.79) | benign(0.017) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
PAGE2 | SNV | Missense_Mutation | novel | c.214N>A | p.Gln72Lys | p.Q72K | Q7Z2X7 | protein_coding | tolerated(0.14) | probably_damaging(0.981) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PAGE2 | SNV | Missense_Mutation | c.41N>A | p.Arg14Lys | p.R14K | Q7Z2X7 | protein_coding | tolerated(0.12) | probably_damaging(0.987) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PAGE2 | SNV | Missense_Mutation | c.182N>A | p.Pro61His | p.P61H | Q7Z2X7 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PAGE2 | SNV | Missense_Mutation | c.302C>G | p.Thr101Ser | p.T101S | Q7Z2X7 | protein_coding | tolerated(0.25) | benign(0.015) | TCGA-G4-6311-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PAGE2 | SNV | Missense_Mutation | c.162N>T | p.Glu54Asp | p.E54D | Q7Z2X7 | protein_coding | tolerated(0.18) | benign(0.02) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
PAGE2 | SNV | Missense_Mutation | c.49N>T | p.Asp17Tyr | p.D17Y | Q7Z2X7 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PAGE2 | SNV | Missense_Mutation | c.200N>G | p.Asp67Gly | p.D67G | Q7Z2X7 | protein_coding | tolerated(0.41) | probably_damaging(0.997) | TCGA-B5-A11J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |